Skip to content
ThetaGradeSign inFree Daily Brief
Not financial advice. ThetaGrade is educational and informational only. Nothing here is a recommendation to buy or sell any security, and it is not tailored to anyone. Options involve substantial risk; read the OCC Characteristics and Risks of Standardized Options. Past performance does not guarantee future results. Methodology

ICCC Immucell

Nasdaq · Health Care · In Vitro & In Vivo Diagnostic Substances · latest quarter in EDGAR: 2026-06-30

Fundamentals
Solid

Immucell (ICCC) is in ThetaGrade’s extended coverage. It does not have a House Rating; this is a fundamentals-only summary from SEC filings, compared with Health Care peers. Overall its fundamentals read Solid (Growth: average; Profitability: above average; Balance sheet: above average). 100% of the method weight is backed by data.

Data as of .

Growth

Average
Revenue growth (TTM, YoY)Average
EPS growth (TTM, YoY)Below average

Profitability

Above average
Operating margin (TTM)Top quintile
Free-cash-flow margin (TTM)Above average

Balance sheet

Above average
Net debt / EBITDAAbove average
Current ratioAverage
Interest coverageTop quintile

From the filings

  • Operating profit (TTM)
  • Revenue up year over year
  • Net cash
  • Free cash flow positive (TTM)

Next earnings

Estimated window 2026-11-04 to 2026-11-20 (rough estimate; estimated from SEC 8-K Item 2.02 filing history (not company-confirmed)). Back-test max error 8 days (> 7).

Why no House Rating

  • market cap under $1B

House Ratings, Weekly Picks and the CSP screen cover the Tier 1 universe only. Methodology

Get rating changes in the free Daily Brief

The market’s key events and signals, digested before the open.

  • ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
  • ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
  • ✓ OPEX, FOMC, CPI and jobs-day reminders

Double opt-in: we email a confirmation link first. No spam, unsubscribe anytime. We never sell your email. Privacy. Educational content, not financial advice.

Free. Want more? See Premium.

Educational summary from public SEC filings; not a House Rating and not financial advice. Sector: SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Source: SEC EDGAR filings. Data as of 2026-10-21.